Back to Journals » Neurobehavioral HIV Medicine » Volume 2

Relationships between the use of second-generation antipsychotics and changes in total cholesterol levels in children and adolescents perinatally infected with HIV

Authors Suad Kapetanovic, Lisa Aaron, Paige L Williams, et al

Published 4 August 2010 Volume 2010:2 Pages 39—48

DOI https://doi.org/10.2147/NBHIV.S12517

Review by Single-blind

Peer reviewer comments 3

Suad Kapetanovic1, Lisa Aaron2, Paige L Williams2, John Farley3, Patricia A Sirois4, Patricia A Garvie5, Deborah A Pearson6, James M Oleske7, Grace Montepiedra2, for the IMPAACT/PACTG 219C Team

1University of Southern California/Keck School of Medicine, Los Angeles, California, USA; 2Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts, USA; 3University of Maryland School of Medicine, Baltimore, Maryland, USA; 4Tulane University School of Medicine, New Orleans, Louisiana, USA; 5St Jude Children’s Research Hospital, Memphis, TN, USA; 6University of Texas Medical School at Houston, Houston, Texas, USA; 7UMDNJ New Jersey Medical School, Newark, New Jersey, USA

Purpose: Perinatally HIV-infected children, who are increasingly aging into adolescence and early adulthood, have significant rates of psychiatric co-morbidities, some of which are treated with second-generation antipsychotics (SGAs). SGAs have been associated with elevated total cholesterol (TC) in youth, but no studies have examined this association in perinatally HIV-infected youth. This study examined changes in TC levels of youth with perinatally acquired HIV infection and co-morbid psychiatric conditions treated with SGAs.

Patients and methods: Long-term changes in TC levels were examined using data from the US multisite prospective Pediatric AIDS Clinical Trials Group 219C cohort study. The change in TC levels from baseline to 12 months after initiating SGA use was compared between 52 SGA-exposed and 148 matched SGA-unexposed perinatally HIV-infected youth, using generalized estimating equation models adjusting for other covariates. The prevalence and time to incident hypercholesterolemia were also compared between these 2 groups.

Results: After adjustment for confounders, 52 youth with prescriptions for SGAs had a larger increase in TC levels than 148 matched youth without antipsychotic prescriptions (mean ­difference = 9 mg/dL, z = 1.96, df = 1, P = 0.0496). Among youth with TC below 220 mg/dL at baseline, 27% of SGA-exposed youth developed hypercholesterolemia (defined as two consecutive TC measurements ≥220 mg/dL), compared with 13% of SGA-unexposed patients (Fisher’s exact test, P = 0.046).

Conclusions: Caution should be used in prescribing SGAs to perinatally HIV-infected youth with psychiatric co-morbidities due to increased risk of hypercholesterolemia. Patients should be monitored, and alternative evidence-based treatments considered when available.

Keywords: HIV-infected youth with psychiatric co-morbidities, second-generation antipsychotics in youth, cholesterol in youth

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Acquired hemophilia A: emerging treatment options

Janbain M, Leissinger CA, Kruse-Jarres R

Journal of Blood Medicine 2015, 6:143-150

Published Date: 8 May 2015

Second case report of successful electroconvulsive therapy for a patient with schizophrenia and severe hemophilia A

Saito N, Shioda K, Nisijima K, Kobayashi T, Kato S

Neuropsychiatric Disease and Treatment 2014, 10:865-867

Published Date: 16 May 2014

The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia

Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al

International Journal of Nanomedicine 2010, 5:581-591

Published Date: 6 August 2010